Heart Failure Society of America 20th Annual Scientific Meeting

Heart Failure Society of America 20th Annual Scientific Meeting | HFSA 2016

The HFSA 2016 annual meeting will feature "something of interest to everyone on the heart failure team," including "significant content in advanced heart failure, pharmacology, patient care, diagnosis and management, devices and technology, and bench-to-bedside translational science."

Conference Coverages

Real-World Challenges to Prescribing Sacubitril/Valsartan for Patients with Heart Failure
Real-World Challenges to Prescribing Sacubitril/Valsartan for Patients with Heart Failure
Patient selection, proper up-titration, and insurance barriers must be considered by cardiologists and other physicians seeking to treat patients with the new combo medication.
Putting New Heart Failure Therapies into Practice
Lack of guidelines and recommendations on use, ill-defined value of care, patient preference, and physicians’ lack of awareness are among the factors that can prevent widespread adoption of new medications.
Researchers Still Looking for Effective Treatment for Heart Failure with Preserved Ejection Fraction
Recent trials involving promising medications to treat patients with heart failure with preserved ejection fraction have not produced significant reductions in mortality.
Monitoring Pulmonary Hypertension to Guide Treatment and Using Sacubitril/Valsartan to Treat Heart Failure Saves Lives
Research results presented at HFSA 2016 support switching from conventional treatment approaches to the new combination treatment.
Looking into the Future of Acute Heart Failure Treatment
A presentation at the 2016 Heart Failure Society of America Scientific Meeting provided details on serelaxin, ularitide, and other new therapies for heart failure.
Pieter Muntendam: Reducing Patients' Hospital Stay VIDEO
Pieter Muntendam, MD, scPharmaceuticals, and colleagues hoped their productive can help reduce patients' length of stay in the hospital.
Providing a New Approach to Patient Care: A Conversation with Pieter Mutendam from scPharmaceuticals VIDEO
At the Heart Failure Society of America's 20th Annual Scientific Meeting, Pieter Muntendam, MD, scPharmaceuticals, discussed his work in developing a hospital strength treatment option for patients with fluid overload using the well known drug furosemide, now for subcutaneous administration.
Joseph Rogers: The Positive Growth of HFSA
According to Joseph Rogers, MD, Duke University, the HFSA has grown positively over the years to become a platform showcasing high level science, as evidenced through the late breakers that were presented.
Joseph Rogers, Duke University: Benefits of Palliative Care VIDEO
Joseph Rogers, MD, Duke University discusses palliative care and how it fits into the overall treatment regimen of very sick patient populations.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$